Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

984 - Identifying Symptom and Quality of Life Improvements in Patients with Carcinoid Syndrome Treated with Telotristat Ethyl: Qualitative Patient Exit Interviews from the TELESTAR Trial

Date

10 Sep 2017

Session

Poster display session

Presenters

Florence Marteau

Citation

Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368

Authors

F. Marteau1, P. Williams2, M. Feuilly1, B. Arnould2

Author affiliations

  • 1 Health Economics & Outcomes Research, Ipsen, 92100 - Boulogne-Billancourt/FR
  • 2 Patient Centered Sciences, Mapi, Lyon/FR
More

Resources

Abstract 984

Background

Carcinoid syndrome (CS) is a rare condition in patients (pts) with neuroendocrine tumors (NETs), characterized by diarrhea, flushing, and abdominal pain that impact health-related quality of life (HRQoL). We assessed symptoms and HRQoL in pts with inadequately-controlled CS enrolled in TELESTAR (NCT01677910).

Methods

English or German-speaking pts randomized 1:1:1 to 12 wks of double-blinded (DB) treatment with telotristat ethyl (TE) 250mg, 500mg, placebo were invited to a blinded, qualitative, semi-structured exit interview after the DB period to assess symptoms, HRQoL concepts (improved/not changed/worsened), and TE treatment effects. Concepts were freely reported by pts and not solicited. EORTC QLQ-C30 and GINET21 questionnaires assessed HRQoL, daily diaries assessed baseline (BL) bowel movement (BM) frequency. Analyses compared pts with durable response (DRs; predefined as BM frequency reduction of ≥ 30% from BL for ≥50% of DB period) and without durable response.

Results

TELESTAR enrolled 135 pts, 45 per group; 34 pts (9, 16, 9 in TE 250mg, 500mg, placebo, respectively), including 10 DRs consented to interviews. BL age, gender, race, BMs/wk of interviewed pts (IPs) were similar to non-interviewed pts. Most qualitative concepts were captured, to an extent, by the QLQ-C30; most common HRQoL qualitative concepts identified were daily life activities, physical, and psychological, with most TE-treated pts improving in these over the DB period. The most common symptoms (improvement/no change) reported in all IPs were diarrhea consistency (n = 17/n=10), frequency (n = 17/n=9), urgency (n = 11/n=7); flushing (n = 11/n=7), and fatigue (n = 9/n=4). A higher proportion of TE-treated pts and DRs reported symptom and HRQoL concept improvements. Durable response (p 

Conclusions

The QLQ-C30 covered most qualitative concepts, but due to the lack of emphasis on key symptoms, may not adequately reflect pt perspectives. Interviews suggested improvements in symptoms and HRQoL with TE treatment and in DRs.

Clinical trial identification

NCT01677910

Legal entity responsible for the study

Lexicon Pharmaceuticals

Funding

Lexicon Pharmaceuticals and Ipsen Pharma SAS

Disclosure

F. Marteau, M. Feuilly: Employee of Ipsen. P. Williams, B. Arnould: Employee of Mapi.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.